MX2019014310A - Agente para prevenir o tratar atrofia cerebral. - Google Patents

Agente para prevenir o tratar atrofia cerebral.

Info

Publication number
MX2019014310A
MX2019014310A MX2019014310A MX2019014310A MX2019014310A MX 2019014310 A MX2019014310 A MX 2019014310A MX 2019014310 A MX2019014310 A MX 2019014310A MX 2019014310 A MX2019014310 A MX 2019014310A MX 2019014310 A MX2019014310 A MX 2019014310A
Authority
MX
Mexico
Prior art keywords
brain atrophy
agent
preventing
suppressing
treating brain
Prior art date
Application number
MX2019014310A
Other languages
English (en)
Inventor
Hiroshi Kobayashi
Yoshihiko Matsumoto
Original Assignee
Fujifilm Toyama Chemical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fujifilm Toyama Chemical Co Ltd filed Critical Fujifilm Toyama Chemical Co Ltd
Publication of MX2019014310A publication Critical patent/MX2019014310A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La presente invención se dirige al problema de proporcionar un agente químico para suprimir la progresión de la demencia del tipo de Alzheimer y un método para suprimir la progresión de la demencia del tipo de Alzheimer. El 1-(3-(2-(1-benzotiofen-5-il)eto xi)propil)azetidin-3-ol o una sal del mismo tiene un efecto de supresión de la atrofia cerebral, y es útil como un agente profiláctico o terapéutico para la atrofia cerebral. Por consiguiente, es posible prevenir o tratar la atrofia cerebral observada en el proceso de envejecimiento o en las enfermedades neurodegenerativas por medio de la administración del 1-(3-(2-(1-benzotiofen-5-il)etoxi)propil)azetidin-3-ol o una sal del mismo.
MX2019014310A 2017-06-02 2018-06-01 Agente para prevenir o tratar atrofia cerebral. MX2019014310A (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
JP2017109885 2017-06-02
JP2017128472 2017-06-30
JP2017145100 2017-07-27
PCT/JP2018/021223 WO2018221729A1 (ja) 2017-06-02 2018-06-01 脳萎縮予防または治療剤

Publications (1)

Publication Number Publication Date
MX2019014310A true MX2019014310A (es) 2022-06-10

Family

ID=64455855

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2019014310A MX2019014310A (es) 2017-06-02 2018-06-01 Agente para prevenir o tratar atrofia cerebral.

Country Status (15)

Country Link
US (1) US11951092B2 (es)
EP (1) EP3632431A4 (es)
JP (2) JP7282028B2 (es)
KR (1) KR20190137936A (es)
CN (3) CN116473962A (es)
AU (1) AU2018276638B2 (es)
BR (1) BR112019024851A2 (es)
CA (1) CA3067453C (es)
IL (1) IL270922A (es)
MX (1) MX2019014310A (es)
NZ (1) NZ759585A (es)
RU (1) RU2759727C2 (es)
SG (1) SG11201911512SA (es)
WO (1) WO2018221729A1 (es)
ZA (1) ZA201907973B (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3632430A4 (en) 2017-06-02 2020-06-10 FUJIFILM Toyama Chemical Co., Ltd. AGENT FOR THE PREVENTION OR TREATMENT OF SPINOCEREBELLOUS ATAXIA
JPWO2018221728A1 (ja) 2017-06-02 2020-04-02 富士フイルム富山化学株式会社 アルツハイマー型認知症予防または治療剤
KR20200003102A (ko) 2017-06-02 2020-01-08 후지필름 도야마 케미컬 가부시키가이샤 아밀로이드 β 단백질량 감소제
BR112019024851A2 (pt) * 2017-06-02 2020-06-09 Fujifilm Toyama Chemical Co Ltd agente para evitar ou tratar atrofia cerebral
EP3705121B1 (en) 2017-10-30 2023-08-30 FUJIFILM Toyama Chemical Co., Ltd. Emopamil binding protein binding agent and use thereof

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2302808C (en) 1997-09-05 2010-05-18 Human Genome Sciences, Inc. 50 human secreted proteins
GB9824207D0 (en) 1998-11-04 1998-12-30 Zeneca Ltd Neurological disorders
BRPI0213393B8 (pt) 2001-10-19 2021-05-25 Fujifilm Toyama Chemical Co Ltd derivados de éter alquílico, ou um de seus sais, processo para produzir um derivado de éter alquílico, derivado de alquil-amida, ou um de seus sais, e, composição farmacêutica
CN100375619C (zh) 2002-06-14 2008-03-19 富山化学工业株式会社 改善脑功能的药物组合物及其用途
CA2521648C (en) 2003-04-17 2012-07-03 Toyama Chemical Co., Ltd. Preventive/remedy for retinal nerve diseases containing alkyl ether derivatives or salts thereof
US8119625B2 (en) * 2006-04-26 2012-02-21 Toyama Chemical Co., Ltd. Neurogenesis inducer or neuropathy therapeutic agent comprising alkyl ether derivative or salt thereof
MX2008013728A (es) 2006-04-26 2009-01-07 Toyama Chemical Co Ltd Inductor de neurogenesis o agente terapeutico de neuropatia que abarca el derivado del eter alkilico o sal del mismo.
AU2009220974B2 (en) 2008-03-04 2013-10-24 Vernalis (R&D) Ltd. Azetidine derivatives
FR2934596B1 (fr) 2008-07-30 2015-04-10 Trophos Nouveaux derives de l'oxime de cholest-4-en-3-one, compositions pharmaceutiques les renfermant, et procede de preparation
US8404711B2 (en) 2009-04-13 2013-03-26 Theravance, Inc. 5-HT4 receptor agonist compounds for treatment of cognitive disorders
CN102802620A (zh) 2009-05-11 2012-11-28 英维沃医药有限公司 使用某种α-7烟酸受体与乙酰胆碱酯酶抑制剂结合治疗认知障碍
WO2011057199A1 (en) 2009-11-06 2011-05-12 Adenios, Inc. Compositions for treating cns disorders
TR201907882T4 (tr) 2012-02-22 2019-06-21 Fujifilm Toyama Chemical Co Ltd 1-(3-(2-(1-Benzotiofen-5-il)etoksi)propil)azetidin-3-olü veya onun tuzunu içeren katı farmasötik bileşim
AU2013292519B2 (en) 2012-07-19 2017-12-07 Drexel University Sigma receptor ligands for modulating cellular protein homeostasis
KR101676212B1 (ko) 2012-10-01 2016-11-14 에프. 호프만-라 로슈 아게 Cns 활성제로서 벤즈이미다졸
EP3100725B1 (en) 2014-01-31 2020-05-06 FUJIFILM Toyama Chemical Co., Ltd. Post nerve injury rehabilitation effect-enhancing agent comprising an alkyl ether derivative or a salt thereof
US20170129915A1 (en) 2014-04-25 2017-05-11 Resilio Company Limited Therapeutic agent for diseases associated with nerve axon dysfunction, including therapeutic agent for alzheimer's disease
WO2015188368A1 (en) 2014-06-13 2015-12-17 Merck Sharp & Dohme Corp. Pyrrolo[2,3-c]pyridines as imaging agents for neurofibrilary tangles
WO2016051799A1 (ja) 2014-10-01 2016-04-07 学校法人同志社 ２－アミノヒドロキノン誘導体及びタウ凝集阻害剤
WO2016124508A1 (en) 2015-02-02 2016-08-11 Ucb Biopharma Sprl 9h-pyrrolo-dipyridine derivatives
US20160324851A1 (en) 2015-05-07 2016-11-10 Axovant Sciences, Ltd. Methods of treating a neurodegenerative disease
EP3308782B1 (en) 2015-06-11 2022-01-19 Toyama Chemical Co., Ltd. Sigma-receptor binding agent
DK3395342T3 (da) 2015-12-25 2020-10-12 Fujifilm Toyama Chemical Co Ltd Tablet omfattende 1-(3-(2-(1-benzothiophen-5-YL)ethoxy)propyl)azetidin-3-ol eller salt deraf
JPWO2018221728A1 (ja) 2017-06-02 2020-04-02 富士フイルム富山化学株式会社 アルツハイマー型認知症予防または治療剤
KR20200003102A (ko) 2017-06-02 2020-01-08 후지필름 도야마 케미컬 가부시키가이샤 아밀로이드 β 단백질량 감소제
JP7370859B2 (ja) 2017-06-02 2023-10-30 富士フイルム富山化学株式会社 タウオパチー予防または治療剤
BR112019024851A2 (pt) * 2017-06-02 2020-06-09 Fujifilm Toyama Chemical Co Ltd agente para evitar ou tratar atrofia cerebral
EP3632430A4 (en) 2017-06-02 2020-06-10 FUJIFILM Toyama Chemical Co., Ltd. AGENT FOR THE PREVENTION OR TREATMENT OF SPINOCEREBELLOUS ATAXIA
EP3705121B1 (en) 2017-10-30 2023-08-30 FUJIFILM Toyama Chemical Co., Ltd. Emopamil binding protein binding agent and use thereof

Also Published As

Publication number Publication date
SG11201911512SA (en) 2020-01-30
NZ759585A (en) 2022-02-25
JP2023053337A (ja) 2023-04-12
AU2018276638B2 (en) 2021-04-08
WO2018221729A1 (ja) 2018-12-06
CN110709078A (zh) 2020-01-17
JPWO2018221729A1 (ja) 2020-04-09
ZA201907973B (en) 2022-03-30
RU2759727C2 (ru) 2021-11-17
BR112019024851A2 (pt) 2020-06-09
US11951092B2 (en) 2024-04-09
RU2019138166A3 (es) 2021-07-09
CN116473962A (zh) 2023-07-25
RU2019138166A (ru) 2021-07-09
CN116492335A (zh) 2023-07-28
EP3632431A4 (en) 2020-06-03
IL270922A (en) 2020-01-30
AU2018276638A1 (en) 2019-12-19
CA3067453A1 (en) 2018-12-06
EP3632431A1 (en) 2020-04-08
US20200215030A1 (en) 2020-07-09
CA3067453C (en) 2021-11-23
KR20190137936A (ko) 2019-12-11
JP7282028B2 (ja) 2023-05-26

Similar Documents

Publication Publication Date Title
NZ759585A (en) Agent for preventing or treating brain atrophy
MX2021010198A (es) Indoles n-sustituidos y otros heterociclos para el tratamiento de trastornos cerebrales.
MX2021001903A (es) Moduladores de regulador de conductancia transmembranal de fibrosis quistica.
MX2021010193A (es) Azepino-indoles y otros heterociclos para el tratamiento de trastornos cerebrales.
MX2019014300A (es) Agente para prevenir o tratar la tauopatia.
MX2020011528A (es) Inhibidores heterociclicos sustituidos de ptpn11.
MX2020001732A (es) Tratamiento de las afecciones del sistema nervioso central.
NZ760919A (en) Compounds, compositions and methods for modulating eukaryotic initiation factor 2b
PH12016501600A1 (en) 2-amino-3, 5, 5-trifluoro-3, 4, 5, 6-tetrahydropyridines as bace1 inhibitors for treatment of alzheimer's disease
MX2020001757A (es) Compuestos, sales de los mismos y metodos para el tratamiento de enfermedades.
EA201890318A1 (ru) СОЕДИНЕНИЯ ЗАМЕЩЕННОГО ПИРАЗОЛО[1,5-a]ПИРИДИНА В КАЧЕСТВЕ ИНГИБИТОРОВ RET КИНАЗЫ
TN2017000134A1 (en) 2-amino-3,5-difluoro-3,6-dimethyl-6-phenyl-3,4,5,6-tetrahydropyridines as bace1 inhibitors for treating alzheimer's disease
SG10201907699YA (en) Substituted pyrazole compounds as serine protease inhibitors
EA201890256A1 (ru) 2-амино-3-фтор-3-(фторметил)-6-метил-6-фенил-3,4,5,6-тетрагидропиридины в качестве ингибиторов bace1
MX2020006237A (es) Compuestos para el tratamiento de enfermedades relacionadas con la expresion de dux4.
MX2019014306A (es) Agente para reducir la cantidad de proteina beta amiloide.
EP3681477A4 (en) IMPROVED METHOD AND COMPOSITION FOR THE TREATMENT OF CONDITIONS, DISEASES OR DISORDERS SENSITIVE TO TRITERPENES
NZ759647A (en) Agent for preventing or treating spinocerebellar ataxia
WO2020021477A3 (en) Compositions and methods for treating the eye
EP3263119A4 (en) Composition including extracellular vesicles derived from bacteria of bacillus sp. for treating pregnancy-associated diseases
MX2017017171A (es) Compuestos terapeuticos y composiciones para el tratamiento de trastornos sociales y trastornos de uso de sustancias.
PH12019500198A1 (en) Compounds and compositions and uses thereof
WO2017221237A8 (en) Fungicidal compositions and methods for controlling plant pathogens
MX2018009662A (es) Metodo y composicion farmaceutica para tratamiento de neurodegeneracion.
MX2018001592A (es) Composiciones y metodos para el tratamiento y la prevencion de trastornos neurodegenerativos.